5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to ProfitThe Motley Fool • 06/12/19
Novartis And Axovant Might Jointly Be Holding The Most Promising Neurodegeneration Drug In DevelopmentSeeking Alpha • 06/04/19
Bothered by the Price Tag of a $2.1 Million Drug? Read This Before Complaining Too MuchThe Motley Fool • 05/30/19
Novartis's Positive Study For Treating Asthma Moves It One Step Closer To MarketSeeking Alpha • 05/29/19